Lancet Oncology

Article	Citations
Use of artificial intelligence to enhance detection of nodal metastases	793
SABR for operable stage I non-small-cell lung cancer: comparison to surgery	722
Patients with cancer in Louisiana denied fertility preservation cover	549
Innovation in gynaecological cancer: highlighting global disparities	492
Combination immunotherapy in chemotherapy in gastric cancer	488
US FDA proposes stronger laboratory test oversight	470
Correction to Lancet Oncol 2022; 23: 1124–26	451
Correction to Lancet Oncol 2021; 22: 309–20	434
COVID-19 pandemic causes cervical cancer screening crisis	420
Medical treatment for active breast cancer brain metastases	390
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	380
IVLBCL mimicking VEXAS syndrome	374
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy	372
The GLOW trial in chronic lymphocytic leukaemia	350
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer	344
Dual therapy in metastatic castration-resistant prostate cancer	322
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply	317
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer	306
Italy to pass law on the right to be forgotten for cancer survivors	304
Palliative radiotherapy for hepatic cancer pain	301
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges	294
Study bolsters concerns about US FDA accelerated drug approvals	291
Olanzapine for chemotherapy-induced nausea and vomiting control	288
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	284
US Surgeon General calls for cancer warning labels on alcohol	283

CAR T cells for the long run in aggressive B-cell lymphoma	280
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study	278
Correction to Lancet Oncol 2021; 22: 1081–92	276
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi	275
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC	271
Antibody–drug conjugates in acute myeloid leukaemia: more research needed	265
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled,	263
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia	262
A new generation of comprehensive precision oncology trials	258
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis	256
The silent malignant mesothelioma epidemic: a call to action	256
Precision medicine for children with cancer	252
The future of precise cancer chronotherapeutics	243
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study	239
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study	235
Survivorship after neoadjuvant chemotherapy	232
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial	227
Impact of COVID-19 on cancer care in India: a cohort study	225
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries	224
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t	224
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial	216
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation	209
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised,	209
Determining the optimal use of approved drugs in oncology	209
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm	209
Concern for cancer drugs in USA–EU tariff war	207
Navigating the complexity: reflections on the development of perioperative cancer treatments	204
Health insurance system in Japan faces risk of politicisation	202
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial	202
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult	194
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery	193
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial	190
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	187
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial	187
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma under	181
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase	181
Focus where it matters: turning insights into advocacy	179
Decentralised, point-of-care CAR-T for multiple myeloma	178
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study	177
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer	177
A biobank perspective on use of tissue samples donated by trial participants	177
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit	175
Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis	171
Common Sense Oncology: including everyone	170
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?	166
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply	164
Essential anticancer medicines for children: defining what matters most for Europe	163
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply	163
Importance of clinical research for the UK's 10-year cancer plan	160
Lung cancer rates highest among British Bangladeshi men	160

Greater price transparency needed for thyroid cancer treatment among US cancer centres	160
Balancing clinical benefit and social value: challenges in HTA assessments	159
Adjuvant therapy in stage IIIA melanoma - Authors' reply	155
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo	153
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:	151
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update	150
Radiotherapy with genomic-adjusted radiation dose	149
Radiotherapy with genomic-adjusted radiation dose	148
Mantle cell lymphoma: is it time for risk-adapted treatment?	148
Lebanon faces critical shortage of drugs	147
India rolls out HPV vaccination	146
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti	144
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis	143
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer	142
Cancer on the agenda during IAEA Director General's visit to Chile	141
Challenges and prospects for cancer treatment in prison settings	140
Daratumumab maintenance in patients with myeloma	140
Correction to Lancet Oncol 2020; 21: 699–709	137
Correction to Lancet Oncol 2023; 24: e242	137
2022 ASTRO annual meeting	136
Clearing the radiotherapy backlog: innovation to pave the way	136
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial	133
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	133
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK	132
A growing vulvar mass in a post-menopausal woman	130
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup	130
Radiotherapy and conflict: from disruption to expansion and hope	129
Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis	128
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire	127
Shortages of essential medications for children with cancer in Colombia	127
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA	126
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study	125
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra	123
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations	122
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	122
Alcohol and the global burden of cancer: what are we missing?	118
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study	117
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer	116
Syrian cancer patients regain treatment access in Türkiye	114
Antimicrobial resistance in patients with haematological malignancies: a scoping review	113
WHO reports health service disruptions due to suspensions of aid	112
The challenges of cancer care for the LGBTQ+ community	111
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer	111
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial	110
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial	109
Mozambique takes on cancer burden challenges	108
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study	108
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group	108
Endometrial cancer: the individual approach	106
Secondary cytoreduction for relapsed ovarian cancer	106
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer	105
Correction to Lancet Oncol 2023; 24: 1181–95	104
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply	104
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting	103
Internationally trained doctors in the USA	103
AACR Annual Meeting 2023	102
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose	101
The thin border between individual and collective ethics: the downside of GDPR	100
Screening for breast cancer brain metastases	99
ROAR trial: which treatment is effective after progression?	98
6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting	97
Correction to Lancet Oncol 2021; 22: 1497–98	96
Correction to Lancet Oncol 2024; 25: e126–35	94
Shortage of cancer drugs in Mexico	94
Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis	93
Transforming cancer: behind the scenes at the Crick Institute	92
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply	90
Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma	88
Study of the Veterans Affairs Health Care System highlights the impact of COVID-19 on cancer diagnoses in the USA	87
Second-line FOLFOX chemotherapy for advanced biliary tract cancer	87
On a precipice: the UK's broken health-care system	86
Promoting cancer prevention through World Cancer Day in Nigeria	85
Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply	84
Medical debt of people with cancer in the USA	84
Pembrolizumab monotherapy for advanced chordoma – Authors' reply	82
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?	82
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care	82
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?	81
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommen	80
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-co	80

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial	79
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402)	79
Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment	79
South Africa's new tobacco and e-cigarette control bill	78
Managing immune checkpoint inhibition in transplant recipients	77
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label,	75
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, singl	75
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group	74
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop	74
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry	74
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-lab	73
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study	73
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply	72
Second-line FOLFOX chemotherapy for advanced biliary tract cancer	70
Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases	70
Intensifying neoadjuvant treatment in locally advanced rectal cancer – Authors' reply	69
Code of practice needed for samples donated by trial participants – Sponsor's reply	69
Quality control and childhood cancer medicines	68
Pilot cancer programmes in Côte d'Ivoire, Kenya, and Zimbabwe	67
Correction to Lancet Oncol 2022; 23: 1297–307	67
Correction to Lancet Oncol 2023; 24: 91–106	66
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply	66
Correction to Lancet Oncol 2023; 24: e472–518	66
Correction to Lancet Oncol 2016; 17: 484–95	66
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply	65
US lawmakers call on Biden Administration to lower the price of enzalutamide	65
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma – Authors' reply	65
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply	65
Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study	64
Medical imaging and nuclear medicine: points to note	63
Sintilimab plus IBI305 for hepatocellular carcinoma	62
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study	62
Enfortumab vedotin for cisplatin-ineligible urothelial cancer	62
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia	61
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma	61
Challenging cancer through poetry	60
Anticipating the future of cancer care in Trump's America	60
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply	60
Stereotactic ablative radiotherapy for primary kidney cancer	60
American Lung Association calls for expanded insurance coverage for lung cancer screening	60
PSMA-PET research: addressing challenges and prospects – Authors' reply	59
18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply	59
New evidence for brain cancer risk after a single paediatric CT scan	59
US legislation might soon allow easier access to cancer medications	59
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic	58
Problems with catch-up HPV vaccination after resumption of proactive recommendations	58
Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer	58
Sharing a personal story behind brain cancer	58
Abemaciclib for malignant pleural mesothelioma – Authors' reply	58
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?	57
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, op	57
Management of locally advanced gastric cancer	57
Sharp increase in patients waiting months for urgent cancer treatment	57
Poor cancer care in Zimbabwe	56
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised	56
Essential medicines list in national cancer control plans: a secondary analysis from a global study	55
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease	55
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study	55
Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer	55
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial	55
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial	54
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean	54
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial	54
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	54
Immunotherapy: balancing the risks and benefits	53
Unresolved questions regarding the promise of the TPEx regimen	53
Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment	53
HPV vaccine roll-out in Nigeria and Bangladesh	52
US Clean Air in the firing line	52
ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma	52
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-02	51
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial	51
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE	51
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study	51
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-a	51
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges	51
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial	50
The changing global landscape of national cancer control plans	49
Secondary prevention of anthracycline cardiotoxicity in childhood cancer survivors	48
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label,	48
Thank you to The Lancet Oncology's reviewers in 2022	48
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?	48
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim resul	48
Real-time fluorescence imaging for cancer surgery: a pathologist's perspective	47
Thoracic CT follow-up after non-small-cell lung cancer resection	47
Cancer in sub-Saharan Africa: key research and action gaps	46
Improved cancer coverage for firefighters in Western Australia	46
Transforming Canada's role in global cancer control	45
Combination chemo-immunotherapy in advanced oesophageal squamous cell carcinoma	45
Indonesia and the Philippines take steps to control cancer	45
FDA decisions on new oncological drugs	44
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer	44
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma	44
Place of death of people with cancer in 12 Latin American countries: a total population study using national death registers	44
Cancer and premature mortality—pushing the frontiers of cancer care	43